Home-based magnetic field stimulation for Parkinson's disease
Patogénesis Cortical De La Enfermedad De Parkinson: Efectos Corticales Y Corticoestriatales De La Estimulación Transcraneal Por Campo Magnético Estático En Pacientes Con Enfermedad De Parkinson
PHASE1 · Fundación de investigación HM · NCT06840678
This study is testing if a new home-based magnetic treatment can help improve movement and motor symptoms in people with Parkinson's disease.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Fundación de investigación HM (other) |
| Locations | 1 site (Móstoles, Madrid) |
| Trial ID | NCT06840678 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the safety and feasibility of home-based transcranial static magnetic field stimulation (tSMS) targeting the supplementary motor area in patients with Parkinson's disease. The study will assess whether this non-invasive intervention can effectively modulate corticostriatal activity, which is crucial for motor control. Participants will be monitored for their clinical response to the treatment, particularly focusing on improvements in motor symptoms. The study is designed to gather preliminary data that could inform larger-scale trials in the future.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with idiopathic Parkinson's disease who respond well to dopaminergic medication.
Not a fit: Patients with MRI-incompatible metal objects, levodopa-induced dyskinesias, or significant neuropsychiatric co-morbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a novel, non-invasive treatment option for improving motor function in patients with Parkinson's disease.
How similar studies have performed: While the specific approach of tSMS is novel, similar non-invasive brain stimulation techniques have shown promise in other studies for treating Parkinson's disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * idiopathic Parkinson's disease (Brain Bank criteria) * optimal clinical response to dopaminergic medication (\>30% MDS-UPDRS-III improvement) Exclusion Criteria: * MRI-incompatible metal objects in the body (e.g. cardiac pacemakers) * presence of levodopa-induced dyskinesias * other main neuropsychiatric co-morbidity
Where this trial is running
Móstoles, Madrid
- HM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales — Móstoles, Madrid, Spain (RECRUITING)
Study contacts
- Principal investigator: Guglielmo Foffani, PhD — HM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales, Móstoles, Madrid, Spain
- Study coordinator: Guglielmo Foffani, PhD
- Email: gfoffani.hmcinac@hmhospitales.com
- Phone: +34 - 91 26 73 201
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Parkinson's Disease